<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04057898</url>
  </required_header>
  <id_info>
    <org_study_id>MN-166-ALS-2301</org_study_id>
    <nct_id>NCT04057898</nct_id>
  </id_info>
  <brief_title>Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS</brief_title>
  <acronym>COMBAT-ALS</acronym>
  <official_title>A Phase 2b/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by Open-Label Extension Phase in Subjects With Amyotrophic Lateral Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MediciNova</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MediciNova</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel group study&#xD;
      to evaluate the efficacy, safety and tolerability of MN-166 given to ALS participants for 12&#xD;
      months followed by a 6-month open-label extension phase.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2b/3 multicenter, randomized, double-blind, placebo-controlled, parallel&#xD;
      group study to evaluate the efficacy, safety and tolerability of MN-166 followed by an&#xD;
      open-label extension phase compared to matching placebo in subjects diagnosed with ALS.&#xD;
&#xD;
      The study will consist of a screening phase (up to 30 days) followed by a double-blind phase&#xD;
      (12 months). Following the screening phase, subjects who continue to meet entry criteria will&#xD;
      be randomly assigned to one of two treatment groups: MN-166 or matching placebo in a 1:1&#xD;
      ratio. Upon completion of the double-blind phase, subjects will be given the option to&#xD;
      continue to the Open-label Extension Phase for a period of six months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 28, 2020</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in ALSFRS-R score at Month 12 (or last measurement before death in case of censoring) and survival time.</measure>
    <time_frame>12 months</time_frame>
    <description>The amyotrophic lateral sclerosis functional rating scale-revised, or ALSFRS-R, measures the functional status of subjects with ALS. It is based on 12 items, each of which is rated on a 5-point scale (0 to 4). The rate of total functional disability thus ranges from 0 (maximum disability) to 48 (normal function) points.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline of muscle strength measured by hand-held dynamometry</measure>
    <time_frame>Baseline, Treatment Phase Week 6, Months 3, 6, 9 and12 time points.</time_frame>
    <description>Hand-held dynamometry, or HHD, is used to measure the force generated by each muscle. The scale ranges from 0 (no visible movement of the part) to 10 (holds test position against strong pressure). Thus, the higher the total score, the higher muscle strength is observed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline on quality of life assessed by ALSAQ-5 at Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>The Amyotrophic Lateral Sclerosis Assessment Questionnaire, or ALSAQ-5, is a patient self-report questionnaire specifically designed to measure 5 areas of health: physical mobility, activities of daily living and independence, eating and drinking, communication and emotional functioning. The subject is asked about 5 different areas of difficulties in their daily lives: ability to stand up, use of limbs, consuming solid food, level of speech coherence, and degree of hope about the future.Each question provides 5 choices from which to choose: Never, Rarely, Sometimes, Often, and Always or cannot do at all.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline of functional activity measured by ALSFRS-R at Month 12</measure>
    <time_frame>12 months</time_frame>
    <description>The ALSFRS-R assessment tool measures the functional status of subjects with ALS. It is based on 12 items, each of which is rated on a 5-point scale (0 to 4). The rate of total functional disability thus ranges from 0 (maximum disability) to 48 (normal function) points. In this context, the ALSFRS-R total score change (lower, same, higher) is documented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responders, measured in percent of subjects overall, whose ALSFRS-R total score was stable or improved</measure>
    <time_frame>12 months</time_frame>
    <description>Proportion of subjects in which ALSFRS-R total score was stable or improved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to survival</measure>
    <time_frame>12 months</time_frame>
    <description>Defined by death or permanent dependency to ventilator or tracheostomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-Related Adverse Events as Assessed by CTCAE v4.0</measure>
    <time_frame>12 months</time_frame>
    <description>The incidence of treatment-emergent adverse events (TEAEs), severity (mild, moderate, severe), as well as relationship to study treatment (not related, possibly related, probably related) and whether they are considered serious.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes from Baseline in Laboratory Values</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of out-of-normal-range values and markedly abnormal change from baseline in laboratory safety test variables by treatment group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">230</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <arm_group>
    <arm_group_label>MN-166</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will take MN-166 10 mg capsules, up to 50 mg twice a day for 12 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will take up to 5 matching placebo capsules twice a day for 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MN-166</intervention_name>
    <description>Subjects will take MN-166 for 12 months followed by a 6-month open-label extension phase.</description>
    <arm_group_label>MN-166</arm_group_label>
    <other_name>ibudilast</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subjects will take matching placebo for 12 months followed by a 6-month open-label extension phase.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects age 18 - 80 years, inclusive;&#xD;
&#xD;
          -  Diagnosis of familial or sporadic ALS as defined by the El Escorial-Revised (2000)&#xD;
             research diagnostic criteria for ALS [clinically definite, clinically probable,&#xD;
             probable-laboratory-supported];&#xD;
&#xD;
          -  ALS onset of ≤18 months from first clinical signs of weakness prior to screening;&#xD;
&#xD;
          -  If currently using riluzole, subject must be on a stable dose for at least 30 days&#xD;
             prior to initiation of study drug;&#xD;
&#xD;
          -  If currently using edaravone, subject should have completed at least 14 days of their&#xD;
             initial treatment cycle prior to initiation of study drug;&#xD;
&#xD;
          -  Last documented pulmonary function test result (i.e., slow vital capacity or forced&#xD;
             vital capacity) must be greater than or equal to 70% predicted;;&#xD;
&#xD;
          -  Able to swallow study medication capsules;&#xD;
&#xD;
          -  No known allergies to the study drug or its excipients;&#xD;
&#xD;
          -  Received pneumococcal vaccine within 6 years prior to starting clinical trial.&#xD;
&#xD;
        Major Exclusion Criteria:&#xD;
&#xD;
          -  ALSFRS-R score of ≤1 on more than one item in the assessment's individual components;&#xD;
&#xD;
          -  Currently diagnosed with a clinically significant psychiatric disorder or dementia&#xD;
             that would preclude evaluation of symptoms;&#xD;
&#xD;
          -  Currently use or treated with parenteral (intramuscular or intravenous) high dose (&gt;25&#xD;
             mg/week) Vitamin B12 within 30 days prior to study drug administration;&#xD;
&#xD;
          -  Poor peripheral venous access that will limit the ability to draw blood as judged by&#xD;
             the Investigator;&#xD;
&#xD;
          -  Currently participating, or has participated in a study with an investigational or&#xD;
             marketed compound or device within 30 days or 5 half-lives, whichever is shorter,&#xD;
             prior to signing the informed consent;&#xD;
&#xD;
          -  Use of tracheostomy or &gt;22/24-hour ventilatory support.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kazuko Matsuda, MD PhD MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Medicinova Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kazuko Matsuda, MD, PhD, MPH</last_name>
    <phone>858-373-1500</phone>
    <email>inquiries@medicinova.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Eon</last_name>
      <phone>714-509-2661</phone>
      <email>eonv@hs.uci.edu</email>
    </contact>
    <investigator>
      <last_name>Namita Goyal, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Donahue</last_name>
      <phone>904-953-3726</phone>
      <email>donahue.megan@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Adrienne Graham</last_name>
      <phone>904-953-3647</phone>
      <email>Graham.Adrienne@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Bjorn Oskarsson, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy Quarles, MPH CCRC</last_name>
      <phone>706-721-0390</phone>
      <email>bquarles@augusta.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristy Bouchard, BS CCRC</last_name>
      <phone>706-721-0390</phone>
      <email>kbouchard@augusta.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Rivner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University IU Health Neuroscience Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandra Guingrich, LPN</last_name>
      <phone>317-963-7382</phone>
      <email>sguingri@iu.edu</email>
    </contact>
    <contact_backup>
      <last_name>Angela Micheels, PT</last_name>
      <phone>317-963-7382</phone>
      <email>amicheel@iu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Cynthia Bodkin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Collin Gerringer</last_name>
      <phone>913-574-0008</phone>
      <email>cgerringer@kumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Katheryn Jennens</last_name>
      <phone>913-945-9932</phone>
      <email>Kjennens2@kumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Omar Jawdat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristen Riley, Ph.D.</last_name>
      <phone>410-955-8511</phone>
      <email>kriley15@jhmi.edu</email>
    </contact>
    <contact_backup>
      <last_name>Alpa Uchil, CRNP</last_name>
      <phone>410-955-8511</phone>
      <email>apalich2@jhmi.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nicholas Maragakis, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hennepin Healthcare Research Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cherie Martinson, BSN</last_name>
      <phone>612-873-2607</phone>
      <email>cmartinson@hhrinstitute.org</email>
    </contact>
    <contact_backup>
      <last_name>Sandra Swanson</last_name>
      <phone>612-518-5351</phone>
      <email>sandyswansonpt@msn.com</email>
    </contact_backup>
    <investigator>
      <last_name>Samuel Maiser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic / Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Turner</last_name>
      <phone>507-284-1223</phone>
      <email>Turner.Michelle@mayo.edu</email>
    </contact>
    <contact_backup>
      <last_name>Carol M Denny</last_name>
      <phone>507-284-5476</phone>
      <email>Denny.Carol@mayo.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nathan Staff, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital for Special Surgery</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Holzberg, MS CCC-SLP</last_name>
      <phone>646-797-8592</phone>
      <email>Holzbergs@hss.edu</email>
    </contact>
    <contact_backup>
      <last_name>Misha Hooda</last_name>
      <phone>646-714-6135</phone>
      <email>HoodaM@hss.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Dale J Lange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sigiriya Smolen</last_name>
      <phone>315-464-1670</phone>
      <email>smolens@upstate.edu</email>
    </contact>
    <contact_backup>
      <last_name>Lena Deb</last_name>
      <phone>315-464-9756</phone>
      <email>DebL@upstate.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jenny Meyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel M Ward, RN</last_name>
      <phone>919-613-2681</phone>
      <email>rachel.m.ward@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kristina Balderson</last_name>
      <phone>919-684-0071</phone>
      <email>Kristina.balderson@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Richard Bedlack, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Brain and Spine Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Adamo</last_name>
      <phone>503-962-1171</phone>
      <email>Ashley.adamo@providence.org</email>
    </contact>
    <contact_backup>
      <last_name>Lauren Brown</last_name>
      <phone>503-962-1173</phone>
      <email>Lauren.brown3@providence.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nicholas Olney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Orzel, RN</last_name>
      <phone>610-402-8447</phone>
      <email>Andrew.Orzel@lvhn.org</email>
    </contact>
    <contact_backup>
      <last_name>Terry Kloiber, RN</last_name>
      <phone>610-402-9543</phone>
      <email>Terry.kloiber@lvhn.org</email>
    </contact_backup>
    <investigator>
      <last_name>Alison Walsh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Allegheny Health Network, Allegheny Neurological Associates</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mike Bucklaw, CRC</last_name>
      <phone>412-359-4776</phone>
      <email>Mike.Bucklaw@AHN.org</email>
    </contact>
    <contact_backup>
      <last_name>Mary Fetter</last_name>
      <phone>412-359-4856</phone>
      <email>Mary.Fetter@AHN.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sandeep Rana, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sejal Smajic</last_name>
      <phone>434-243-0355</phone>
      <email>SS4YN@hscmail.mcc.virginia.edu</email>
    </contact>
    <contact_backup>
      <last_name>Mary Wagoner</last_name>
      <phone>434-924-5541</phone>
      <email>Miw9b@virginia.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Goran Rakocevic, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Swedish Neuroscience Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Reola</last_name>
      <phone>206-320-3695</phone>
      <email>Jennifer.reola@swedish.org</email>
    </contact>
    <contact_backup>
      <last_name>Hannah Kreinbrink</last_name>
      <phone>206-320-7121</phone>
      <email>Hannah.Kreinbrink@swedish.org</email>
    </contact_backup>
    <investigator>
      <last_name>Michael Elliott, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McMaster University Medical Center</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniela Trapsa</last_name>
      <phone>905 521 2100</phone>
      <phone_ext>76368</phone_ext>
      <email>trapsd@mcmaster.ca</email>
    </contact>
    <contact_backup>
      <last_name>Jane Allan</last_name>
      <phone>905 521 2100</phone>
      <phone_ext>76368</phone_ext>
      <email>allanjane@HHSC.CA</email>
    </contact_backup>
    <investigator>
      <last_name>John Turnbull, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sunnybrook Research Institute</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonam Dubey</last_name>
      <phone>416-480-6860</phone>
      <email>sdubey@sri.utoronto.ca</email>
    </contact>
    <contact_backup>
      <last_name>Hajara Abdiraham</last_name>
      <phone>(416)-480-6100</phone>
      <phone_ext>87561</phone_ext>
      <email>hajara.abdirahman@sri.utoronto.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Lorne Zinman, MD MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Montreal Neurological Institute and Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3A 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathias Couillard</last_name>
      <phone>514-398-6083</phone>
      <email>Mathias.Couillard@mcgill.ca</email>
    </contact>
    <contact_backup>
      <last_name>Natalie Saunders, M.Sc.A.OT.</last_name>
      <phone>514-398-6526</phone>
      <email>Natalie.Saunders@mcgill.ca</email>
    </contact_backup>
    <investigator>
      <last_name>Angela Genge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://medicinova.com/medicinova-webinar/</url>
    <description>This webinar explains the COMBAT-ALS study design and background of MN-166 (ibudilast) as a potential treatment for ALS.</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>August 27, 2021</last_update_submitted>
  <last_update_submitted_qc>August 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>MN-166</keyword>
  <keyword>ibudilast</keyword>
  <keyword>amyotrophic lateral sclerosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibudilast</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

